Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.30 |
| ▸ | CTRC | Q99895 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859055 | 0.81 | MAPT (0.33) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL5911742 | 0.74 | MAPT (0.31) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL28327785 | 0.70 | MAPT (0.32) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL14501295 | 0.69 | BRD4 (0.36) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL14501346 | 0.69 | GAA (0.38) | ALDH1A1PRSS1F2POLB | |
| SCHEMBL2880175 | 0.67 | MAPT (0.33) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL14879881 | 0.67 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL19283814 | 0.66 | MAPT (0.32) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL5911724 | 0.66 | MAPT (0.32) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10385807 | 0.66 | CYP19A1 (0.33) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223795-B2 | Modified peptide derivatives and methods of use thereof | CYCLACEL LIMITED (GB) | 2007-05-29 | — | — | US | disclosed |
| EP-1343754-B1 | CYCLOPHILIN-BINDING LIGANDS | CYCLACEL LTD (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-20040077829-A1 | Modified peptide derivatives and methods of use thereof | CYCLACEL LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1343754-A2 | CYCLOPHILIN-BINDING LIGANDS | Cyclacel Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048178-A2 | CYCLOPHILIN-BINDING LIGANDS | CYCLACEL LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077829-A1 | Modified peptide derivatives and methods of use thereof | NGLY1, NPY1R, NPY2R | ALDH1A1 3858/4885MAPT 4827/4885PRSS1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.